News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Requests Teleconference to Discuss Repros Therapeutics Inc. (RPRX) Phase 2 Protocol for Proellex® in the Treatment of Endometriosis Last Week of August


7/31/2012 9:40:38 AM

THE WOODLANDS, Texas, July 30, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has scheduled a meeting to discuss the design of a Phase 2 endometriosis protocol for low dose oral Proellex®. The teleconference will be held during the last week of August 2012. The Company has submitted the Phase 2 protocol for FDA review. The Company looks forward to the Agency's advice.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES